REG - Genedrive PLC - Block Listing Application to AIM

GenedriveAnnouncement

15/05/2023 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230515:nRSO4802Za&default-theme=true

RNS Number : 4802Z  Genedrive PLC  15 May 2023

genedrive plc

("genedrive" or the "Company")

 

Block Listing Application to AIM

 

London, UK - 15 May 2023: genedrive plc (LSE: GDR), the point of care
molecular diagnostics company, announces applications have been made to AIM
for the admission to trading on the London Stock Exchange for the following
block listings of Ordinary Shares of 1.5 pence each in the Company ("Ordinary
Shares"):

 

•             2017 Share Option Scheme (1,150,588 Ordinary
Shares)

•             Unapproved Share Option Scheme (2,668,144 Ordinary
Shares)

 

The Ordinary Shares may be issued from time to time for outstanding employee
incentive vested share options not yet exercised. New Ordinary Shares issued
following option exercises and admitted to trading under the block admission
will rank pari passu in all respects with the existing Ordinary Shares.

 

The block listing is expected to become effective on 19 May 2023. The Company
will make six-monthly announcements of the utilisation of the block admission,
in line with its obligations under AIM Rule 29.

 

At the time of this announcement, Genedrive has 99,049,946 Ordinary Shares in
issue. This figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

For further information, please contact:

 

 genedrive plc                         +44 (0) 161 989 0245
 David Budd (Chief Executive Officer)
 Russ Shaw (Chief Financial Officer)

 Peel Hunt LLP - Nominated Adviser, Joint Broker                                                      +44 (0) 20 7148 8900
 James Steel / Oliver Duckworth

 finnCap Ltd - Joint Broker                          +44 (0) 20 7220 0500
 Geoff Nash / George Dollemore

 Walbrook PR - Financial PR & IR Adviser                       +44 (0) 20 7933 8780
 Paul McManus / Anna Dunphy            Or Genedrive@walbrookpr.com (mailto:Genedrive@walbrookpr.com)

 

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com) )

 

genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and robust point
of need molecular diagnostics platform for the diagnosis of infectious
diseases and for use in patient stratification (genotyping), pathogen
detection and other indications. The company are currently developing a
genetic test for CYP2C19 metaboliser status.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSQELFFXELEBBF